Treatment of inflammatory myopathies

Muscle and Nerve

Volumn 20, Issue 6, 1997, Pages 651-664

  Mastaglia, Frank L ^a   Phillips, Beverley A ^a   Zilko, Paul ^a  

^a PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

dermatomyositis; inclusion body myositis; inflammatory myopathies; polymyositis; treatment

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE;

CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DIAGNOSTIC APPROACH ROUTE; DRUG EFFICACY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; INFLAMMATION; LYMPH NODE IRRADIATION; MUSCLE FUNCTION; POLYMYOSITIS; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; TREATMENT PLANNING;

DERMATOMYOSITIS; HUMANS; IMMUNOTHERAPY; MYOSITIS, INCLUSION BODY; POLYMYOSITIS;

EID: 0030912055     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(199706)20:6<651::AID-MUS1>3.0.CO;2-7     Document Type: Review

References (12)

1. Al-Janadi M, Smith CD, Harsh J: Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymositis/dermatomyosius. J Rheumatol 1989;16:1592-1596.
2. Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT: Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994;444:1516-1518.
3. Arahata K, Engel AG: Monoclonal antibody analysis of mononuclear cells in myopathies: I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193-208.
4. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: inhibition of NF-kB activity through induction of IkB synthesis. Science 1995; 270:286-290.
5. Barnes BE: Dermatomyositis and malignancy. A review of the literature. Ann Intern Med 1976;84:68-76.
6. Basta M, Dalakas MC: High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-1735.
7. Bertorini TE, Nance AM, Horner LH, Greene W, Gelfand MS, Jaster JH: Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve 1996;19: 388-391.
8. Brooks BR, Sufit RL, dough JA, Conrad J, Sanjak M, Schram M, Erikson LM: Isokinetic and functional evaluation of muscle strength over time in amyotropic lateral sclerosis, in Munsat TL (ed): Quantification of Neurologic Deficit. Boston, Butterworths, 1989, pp. 143-154.
9. Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG: Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 1980;92:365-369.
10. Bunch TW: Prednisone and azathioprine for polymyositis: long-term followup. Anthritis Rheum 1981;24:45-48.
11. Byrne E, Dennett X: Idiopathic inflammatory myopathies: clinical aspects, in Mastaglia FL (ed): Inflammatory Myopathies. Baillièie's Clinical Neurology. London, Baillière Tindell, 1993, pp 499-526.
12. Cancela CT, Anfonso G, Carlo JR: High-dose intravenous immunoglobulin in polymyositis: our clinical experience. Muscle Nerve 1995;18:10:1043.